Search

Sarepta Therapeutics Inc

Open

SectorGezondheidszorg

16.47 -0.36

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

16.14

Max

16.76

Belangrijke statistieken

By Trading Economics

Inkomsten

-355M

-28M

Verkoop

-20M

381M

K/W

Sectorgemiddelde

862

68.089

EPS

-0.1

Winstmarge

-7.463

Werknemers

835

EBITDA

-28M

1.8M

Aanbevelingen

By TipRanks

Aanbevelingen

Neutraal

12 Maanden Prognose

+29.1% upside

Marktinformatie

By TradingEconomics

Marktkapitalisatie

-86M

1.8B

Vorige openingsprijs

16.83

Vorige sluitingsprijs

16.47

Sarepta Therapeutics Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

11 nov 2026, 21:06 UTC

Sarepta Therapeutics, Inc. is trading higher in Wednesday's session, recovering from an earlier decline while remaining below its 20-day moving average.

10 nov 2026, 21:02 UTC

Social Media
News

Sarepta Therapeutics upgraded to Hold by Deutsche Bank, with the price target raised to $18 from $14, despite a significant decline in stock price today.

9 nov 2026, 23:06 UTC

Sarepta Therapeutics, Inc. shares advanced modestly in after-market hours, reaching a high that indicates a slight gain from Monday's close.

6 nov 2026, 21:03 UTC

Macro Event
News

RBC Capital raises Sarepta Therapeutics' price target to $18.00, citing strong Q3 results with adjusted EPS of $0.13 and revenue guidance increase of $50 million.

5 nov 2026, 23:31 UTC

News

Sarepta Therapeutics reported Q3 adjusted EPS of $0.13 and revenue of $381.4 million, but projected Q4 revenue at Q3 levels, raising investor concerns.

4 nov 2026, 21:07 UTC

Sarepta Therapeutics, Inc. shares are advancing as the broader market gains momentum, settling above its 20-day moving average and near the upper end of its one-month trading range.

3 nov 2026, 20:46 UTC

Sarepta Therapeutics, Inc. is trading higher, extending gains from Monday's close and remaining above its 20-day moving average despite a slight retracement.

2 nov 2026, 20:36 UTC

Sarepta Therapeutics, Inc. shares fell, continuing a three-session decline.

30 okt 2026, 23:51 UTC

Sarepta Therapeutics, Inc. is trading modestly higher in after-market hours after a strong upward movement from a low point shortly after the market closed.

29 okt 2026, 23:21 UTC

Sarepta Therapeutics, Inc. is trading lower in after-market hours, influenced by a broader market decline despite an earlier session rebound.

28 okt 2026, 19:46 UTC

Sarepta Therapeutics, Inc. is trading higher, reaching a peak cumulative return amid broader market strength and remaining above its 20-day moving average.

27 okt 2026, 23:21 UTC

Sarepta Therapeutics, Inc. shares declined in after-hours trading, reaching a low shortly after the market closed before a slight recovery.

26 okt 2026, 23:11 UTC

Sarepta Therapeutics Inc is declining in after-market trading, moving lower alongside the broader market after retracing from an earlier gain.

23 okt 2026, 20:07 UTC

Sarepta Therapeutics Inc shares fell amid broader market losses, influenced by rising oil prices, geopolitical tensions, and mixed economic indicators.

22 okt 2026, 20:07 UTC

Shares of Sarepta Therapeutics Inc are declining, following an early peak and midday drop.

21 okt 2026, 23:56 UTC

Sarepta Therapeutics Inc's shares are trading higher in after-market hours, following a day of fluctuating returns with prices ranging from a high of 0.48% to a low of -1.58%.

20 okt 2026, 20:01 UTC

Sarepta Therapeutics Inc is advancing, continuing its upward trend with gains since Monday's close, despite an earlier pullback from a session high.

16 okt 2026, 20:07 UTC

Social Media

Sarepta Therapeutics Inc shares are declining, continuing a downward trend from Thursday's close, despite new data suggesting safe administration of Elevidys to younger boys.

15 okt 2026, 20:02 UTC

Event

Sarepta Therapeutics presents new preclinical data on SRP-1003 at the Oligonucleotide Therapeutics Society meeting, showing promise for treating myotonic dystrophy type 1.

14 okt 2026, 20:07 UTC

News
Social Media
Event

Sarepta Therapeutics presented new preclinical data showing SRP-1003 achieved approximately 80% knockdown of pathogenic DMPK RNA, advancing treatment for myotonic dystrophy type 1.

13 okt 2026, 20:01 UTC

Sarepta Therapeutics Inc shares fell sharply, continuing a notable decline that has kept the stock well below its 20-day moving average.

12 okt 2026, 23:11 UTC

Sarepta Therapeutics Inc shares are trading modestly higher in after-market hours, following a period of notable decline and unusual trading behavior since Monday's close.

9 okt 2026, 20:07 UTC

Macro Event

Sarepta Therapeutics shares fell sharply, reaching a low mid-morning, amid broader market declines following a drop in the Michigan Consumer Sentiment Index to 46.3.

8 okt 2026, 20:06 UTC

News

Sarepta Therapeutics Inc shares are advancing as the broader market rebounds, with cumulative returns exceeding 4% since Wednesday.

6 okt 2026, 19:15 UTC

Sarepta Therapeutics Inc shares fell sharply, moving from an early gain to a significant decline and remaining below the 20-day moving average.

5 okt 2026, 23:40 UTC

Sarepta Therapeutics Inc is trading modestly lower in after-market hours, continuing a trend of declines over the last five sessions amid broader biotechnology sector weakness.

2 okt 2026, 19:35 UTC

Sarepta Therapeutics Inc shares fell, marking a fifth consecutive session of lower closes, amid broader market weakness contributing to a significant monthly decline.

1 okt 2026, 23:30 UTC

Sarepta Therapeutics Inc. advanced in after-market trading, gaining ground after Thursday's close, despite being below its 20-day moving average.

30 sep 2026, 23:30 UTC

News
Event

Sarepta Therapeutics shares are trading higher in after-market hours following new data on ELEVIDYS presented at the World Muscle Society Congress.

29 sep 2026, 19:15 UTC

Sarepta Therapeutics Inc shares fell sharply, currently trading significantly below its 20-day moving average and near the lower end of its one-month range.

Peer Vergelijking

Prijswijziging

Sarepta Therapeutics Inc Prognose

Koersdoel

By TipRanks

29.1% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 21.533 USD  29.1%

Hoogste 38 USD

Laagste 5 USD

Gebaseerd op 18 Wall Street-analisten die 12-maands prijsdoelen bieden voor Sarepta Therapeutics Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Neutraal

18 ratings

3

Buy

11

Hold

4

Sell

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Sarepta Therapeutics Inc

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene. The company is also developing SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Genevant Sciences; University of Florida; Dyno Therapeutics; Hansa Biopharma; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.
help-icon Live chat